A venture-backed pre-commercial biotech. The client had a novel MOA with two potential paths to market: direct anticancer strategy or one based on the agents immunomodulatory anticancer effects
PC data suggested that the small molecule could provide both inhibition of a common cell signaling pathway terminal kinase and may have a role in regulating T cells and their recruitment for effector function
identification of optimal indications based on PoC, timing to value inflection, and partnerabilty
The team took a systematic approach to prioritising indications based on clinical and commercial risks and attractiveness. We conducted an opportunity assessment on top indications to determine the best positioning (including biomarker-driven strategy) to inform target product profile development and provided a 10-year market forecast for direct comparison between top indications.
We enabled the client to strategise their portfolio by triaging indications and identifying new indications that were not previously championed internally. The team provided optimal registrational settings and clinical development strategies to inform partnering discussions, which led to the formation of a clinical collaboration with a large biopharma
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us